Scarica l'app Stockscreener
34.20
1.50%
-0.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Indivior Pharmaceuticals Inc Borsa (INDV) Ultime notizie
Indivior Pharmaceuticals, Inc. (INDV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Third-quarter results are due at 7 a.m. Oct. 29 from Indivior. - Stock Titan
With 77.27% of shares represented, Indivior (INDV) stockholders vote on merger-related share issuance. - Stock Titan
A $1B special dividend features in Indivior (INDV)'s revised merger valuation details. - Stock Titan
Indivior stock pre-market at EUR 32.10: plus 0.00 percent - AD HOC NEWS
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth - GlobeNewswire Inc.
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Three parties report a passive holding above 5% in Indivior (INDV). - Stock Titan
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - Business Wire
Indivior (NASDAQ: INDV) Announces Conditional $8.13 Special Dividend Pending Merger Completion - Kalkine Media
Indivior Declares $8.13 Per Share Special Dividend Tied to Supernus Merger Closing - Minichart
An $8.13 cash payout at Indivior (INDV) hinges on a merger closing - Stock Titan
Indivior declares $8.13 special dividend contingent on merger - Investing.com India
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior
Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing - Quiver Quantitative
Indivior declares $8.13 special dividend contingent on merger - Investing.com
Indivior Pharmaceuticals, Inc. SEC Filing (Sep 14, 2026) - Stock Titan
$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan
Indivior stock gains as Supernus merger and special dividend plan come into focus - ad-hoc-news.de
Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan
SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion - TradingView
Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de
Indivior stock rises on strong Q2 2026 earnings and higher full-year guidance - AD HOC NEWS
Indivior stock gains on raised 2026 outlook and strong Sublocade growth - AD HOC NEWS
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Price to earnings forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indiv - The National Law Review
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Indivior stock trades below fair value as latest earnings beat expectations - AD HOC NEWS
Why Indivior Pharmaceuticals (INDV) Is Back In The Spotlight - sahmcapital.com
Indivior Pharmaceuticals CAO Woodrow D. Anderson Acquires 1,500 Shares at $35.69 Each - Kalkine Media
Indivior (INDV) accounting chief adds 1,500 shares in market or private buy - Stock Titan
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan - Yahoo Finance
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks? - Yahoo Finance
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - theglobeandmail.com
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.3% -- GF Value Says Still Overvalued - GuruFocus
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - ad-hoc-news.de
Indivior stock edges higher as options activity and analyst targets point to further upside - Ad-hoc-news.de
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Indivior Q2 2026 Earnings Call: Complete Transcript - Benzinga
Indivior (INDV) Gains 2.07% to $39.01 as Opioid Addiction Treatment Demand Lifts Pharma StockBreakout Trade - vinanet.vn
Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV - TradingView
Is Indivior Pharmaceuticals (INDV) Below Fair Value Despite A 194% Return? - webull.com
Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView
Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
3.06%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):